AnFilia is a clinical-stage AI company delivering the world's first neuro-specific foundation model — purpose-built from the ground up to detect Alzheimer's, Parkinson's, and Autism risk up to a decade before symptoms emerge, using standard structural MRI.
Neurological diseases begin their biological cascade silently — long before any visible symptom, long before any standard test can detect them. The clinical community is systematically missing the only window in which early intervention can make a meaningful difference.
Alzheimer's, Parkinson's, and neurodevelopmental disorders begin their biological progression up to a decade before a single symptom appears. Standard diagnostics only trigger after irreversible damage is done.
Current clinical workflows rely on visible structural atrophy detected by radiologists. By the time atrophy is visible, the therapeutic window for intervention has often closed.
General-purpose AI models break down across different MRI scanner manufacturers and acquisition protocols — making them clinically non-deployable at scale without scanner-specific retraining.
Developing clinically valid, neuro-specific deep learning requires a rare convergence of neuroimaging science, large-scale ML architecture, and years of multi-site longitudinal research — a combination virtually unavailable in a single team.
A purpose-built clinical AI platform — not a general model adapted for medicine, but a neuro-specific architecture conceived, designed, and validated entirely for the neuroimaging context by domain experts with a decade of hands-on research.
AnFilia's "Scanner-Aware" preprocessing layer neutralizes acquisition variability across GE, Siemens, and Philips systems — enabling deployment in any clinical environment without site-specific retraining or hardware upgrades.
The AnFilia foundation model was architected and trained entirely for neuro-risk detection — not fine-tuned from a general-purpose vision model. Built on years of expert-curated, multi-site longitudinal neuroimaging research, delivering accuracy no off-the-shelf model can match.
No new hardware. No workflow overhaul. Clinicians upload standard structural scans to AnFilia's secure, HIPAA-compliant cloud and receive an objective, explainable risk stratification report within minutes.
A four-stage intelligent pipeline that fits invisibly into existing radiology and clinical workflows — no training, no integration overhead.
Clinicians upload standard structural MRI from any certified scanner via AnFilia's HIPAA-compliant secure portal. No proprietary hardware required.
Proprietary preprocessing normalizes cross-scanner and cross-protocol variability — creating a unified neuro-structural representation regardless of acquisition source.
AnFilia's ground-up neuro-specific foundation model analyzes subtle structural biomarkers — patterns invisible to the human eye and undetectable by conventional radiological review.
A clinician-ready, explainable risk stratification report is generated — flagging at-risk individuals years before symptom onset, enabling early intervention.
AnFilia's methodology is grounded in a decade of high-impact academic research, peer-reviewed and published in the world's most rigorous scientific journals. This is not a prototype — it is a technology forged through years of hands-on research at the frontier of neuroimaging AI.
AnFilia's moat is built into the foundation — years of expert-level neuroimaging research, a model trained from scratch on carefully curated multi-site data, and clinical validation at depth that no fast follower can replicate overnight.
Validated predictive accuracy for early-stage neurological risk — demonstrated on rigorously held-out data from multi-site longitudinal neuroimaging cohorts spanning thousands of subjects.
The model's foundation is over a decade of hands-on experience acquiring, curating, and training on large-scale neuroimaging datasets — institutional knowledge that cannot be replicated from public sources alone.
AnFilia is currently in structured clinical validation with partner hospital systems — calibrating performance on real-world patient populations to meet clinical-grade regulatory standards.
AnFilia creates defensible, quantifiable value across the neurological care continuum — from frontline clinical settings to pharmaceutical R&D.
Objective AI-assisted neuro-risk stratification supplements radiologist assessment, reduces missed early-stage pathology, and unlocks new billable AI-assisted screening codes — creating measurable clinical and financial ROI.
Identify and enrich clinical trial cohorts with individuals at precisely defined disease risk stages — dramatically improving trial efficiency, reducing screen-failure rates, and compressing R&D timelines by years.
Early risk identification enables evidence-based preventive intervention — giving patients, families, and clinicians a multi-year head start to slow disease progression and optimize care planning before symptoms emerge.
We are selectively onboarding health systems, radiology groups, and pharmaceutical R&D teams into our clinical pilot program. Pilot capacity is strictly limited. Apply now to secure your position.
For hospitals, radiology groups, and pharma R&D only. We will follow up personally within 48 hours.
✅ Application received. Our team will be in touch within 48 hours.